EP1242441A4 - Kodon optimierte hiv-1 nef und modifiziertes hiv-1 nef exprimierende polynucleotidimpfstoffe - Google Patents

Kodon optimierte hiv-1 nef und modifiziertes hiv-1 nef exprimierende polynucleotidimpfstoffe

Info

Publication number
EP1242441A4
EP1242441A4 EP00989282A EP00989282A EP1242441A4 EP 1242441 A4 EP1242441 A4 EP 1242441A4 EP 00989282 A EP00989282 A EP 00989282A EP 00989282 A EP00989282 A EP 00989282A EP 1242441 A4 EP1242441 A4 EP 1242441A4
Authority
EP
European Patent Office
Prior art keywords
nef
hiv
codon optimized
polynucleotide vaccines
vaccines expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00989282A
Other languages
English (en)
French (fr)
Other versions
EP1242441A2 (de
Inventor
John W Shiver
Xiaoping Liang
Tong-Ming Fu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1242441A2 publication Critical patent/EP1242441A2/de
Publication of EP1242441A4 publication Critical patent/EP1242441A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00989282A 1999-12-17 2000-12-15 Kodon optimierte hiv-1 nef und modifiziertes hiv-1 nef exprimierende polynucleotidimpfstoffe Withdrawn EP1242441A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17244299P 1999-12-17 1999-12-17
US172442P 1999-12-17
PCT/US2000/034162 WO2001043693A2 (en) 1999-12-17 2000-12-15 Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef

Publications (2)

Publication Number Publication Date
EP1242441A2 EP1242441A2 (de) 2002-09-25
EP1242441A4 true EP1242441A4 (de) 2004-04-14

Family

ID=22627710

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00989282A Withdrawn EP1242441A4 (de) 1999-12-17 2000-12-15 Kodon optimierte hiv-1 nef und modifiziertes hiv-1 nef exprimierende polynucleotidimpfstoffe

Country Status (5)

Country Link
EP (1) EP1242441A4 (de)
JP (1) JP2003516741A (de)
AU (1) AU782193B2 (de)
CA (1) CA2393861A1 (de)
WO (1) WO2001043693A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
CA2398816A1 (en) 2000-02-04 2001-08-09 Duke University Human immunodeficiency virus vaccine
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2002362368B2 (en) * 2001-09-20 2006-09-21 Glaxo Group Limited HIV-gag codon-optimised DNA vaccines
ES2560449T3 (es) 2004-05-28 2016-02-19 Oryxe Una mezcla para administración transdérmica de compuestos de peso molecular bajo y alto
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
MX2007003214A (es) * 2004-09-17 2007-10-11 Centelion Formulaciones liquidas estables de adn plasmidico.
EP2185195A2 (de) 2007-08-16 2010-05-19 Tripep Ab Immunogen-plattform
PL229124B1 (pl) 2015-02-10 2018-06-29 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepionka DNA skierowana przeciwko wirusowi grypy H5N1, zmodyfikowana sekwencja nukleotydowa oraz zastosowanie zmodyfikowanej nukleotydowej sekwencji do wytwarzania szczepionki

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022080A2 (en) * 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851813A (en) * 1990-07-12 1998-12-22 President And Fellows Of Harvard College Primate lentivirus antigenic compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022080A2 (en) * 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0143693A3 *

Also Published As

Publication number Publication date
AU782193B2 (en) 2005-07-07
WO2001043693A2 (en) 2001-06-21
WO2001043693A3 (en) 2002-02-21
AU2581001A (en) 2001-06-25
EP1242441A2 (de) 2002-09-25
JP2003516741A (ja) 2003-05-20
CA2393861A1 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
AU9456201A (en) Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
HUP0004896A3 (en) Fusion proteins comprising hiv-1 tat and/or nef proteins
GB2349349B (en) Adjustable-volume vessel
ZA200201816B (en) A vaccine composition and method of using the same.
EP1242441A4 (de) Kodon optimierte hiv-1 nef und modifiziertes hiv-1 nef exprimierende polynucleotidimpfstoffe
HK1031725A1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use
EP1242124A4 (de) Polynukleotid-impfstoffe, die kodon-optimiertes hiv-1 pol und modifiziertes hiv-1 pol exprimieren
EP1299410A4 (de) Gfr-alpha-1-ret-spezifische agonisten und ihre methoden
GB0002810D0 (en) Vessel
IL147733A0 (en) Ehrlichia canis genes and vaccines
SI1043306T1 (en) 3-amino-3-arylpropan-1-ol-derivates, their preparation and use
GB2347612B (en) Wrist and hand support
GB0017224D0 (en) Hand and wrist support
AU2001270209A1 (en) Hiv-1 vaccines and screening methods therefor
HUP0203678A3 (en) Nitro-sulfobenzamide-derivatives, preparation and use thereof
IL146940A0 (en) Novel calpains and their use
GB9929581D0 (en) Comjpositions and their use
GB9927353D0 (en) Virus preparation and use
GB0029191D0 (en) Vessels
EG21695A (en) Pin-screw-ajusting and safe
GB9927960D0 (en) Locket
TW397124U (en) Secretive safe
HUP0105189A3 (en) Organoprotective solutions and their use
GB9903538D0 (en) Polynucleotide constructs and uses therof
GB9922009D0 (en) CCR5 Modulators

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17P Request for examination filed

Effective date: 20020821

A4 Supplementary search report drawn up and despatched

Effective date: 20040226

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 39/00 B

Ipc: 7C 07K 14/16 B

Ipc: 7C 12N 15/00 B

Ipc: 7A 61K 48/00 B

Ipc: 7C 12N 15/09 B

Ipc: 7C 07H 21/04 A

Ipc: 7A 61P 31/18 B

Ipc: 7A 61K 39/39 B

17Q First examination report despatched

Effective date: 20051110

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080304